Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-05-21
Intellia Therapeutics, Inc.
Clinical-stage biotech developing in vivo CRISPR gene-editing medicines for hereditary angioedema, transthyretin amyloidosis and other severe diseases.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Crossing from platform story to commercial gene editing
The opportunity is a shift from precommercial CRISPR science to an approved rare-disease franchise. The upside is meaningful, but it only converts if approval, payer access and physician trust arrive in sequence.

Analysis

Thesis
If lonvo-z clears FDA and launches well, Intellia can shift from a collaboration-funded platform to a real rare-disease gene-editing franchise with reusable clinical, payer and treatment-center infrastructure; that approval-to-commercial conversion creates a realistic path to multi-bagger equity value by 2031.
Last Economy Alignment
AI helps Intellia design, learn and scale evidence faster, but value capture still sits in regulated medicines, proprietary human data and trust with payers and doctors. This is a positive AI-era setup, yet the main bottlenecks remain biology, FDA permissioning and launch execution rather than software-like network effects.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.6x (from 4 most recent analyses)
Reasoning
The upside case is a reclassification. Today the market mostly values platform promise and cash; by 2031 it could value an approved rare-disease franchise with one proven commercial product, follow-on pipeline credibility and monetizable platform know-how. I cap the rerating below top rare-disease compounders because one-time therapy adoption should ramp gradually, ATTR still needs proof, and dilution has already increased the share base.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not that the science is obviously broken; it is that Intellia is now entering the narrowest part of the funnel where approval, safety interpretation, payer design and first-launch execution all matter at once. Lonvo-z is the value anchor, so any delay, restrictive label or weak real-world conversion would hit both near-term revenue and the platform premium. ATTR remains important because a clean rebound would broaden the franchise, while another setback would reinforce the view that Intellia is a one-product story.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They do not sell software that AI can copy; they are trying to own a regulated medicine, the clinical data around it and the treatment workflow. AI helps the science, but the real bottlenecks are FDA approval, safety trust and getting doctors and payers comfortable with a one-time edit.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$26.65
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case